{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"83.2","upperLimit":"93.4","value":"88.3"},{"groupId":"OG001","lowerLimit":"86.3","upperLimit":"91.4","value":"88.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"634"}],"units":"Participants"}],"description":"EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"T-ALL patients on AALL1231 who did not receive prophylactic cranial radiation and did not receive bortezomib: Intermediate Risk T-ALL (exclude CNS3) and SR T-ALL (exclude those who met AALL0434 Low Risk definition).","id":"OG000","title":"AALL1231 T-ALL Patients"},{"description":"T-ALL patients on AALL0434 \\[NCT00408005\\] who received prophylactic cranial radiation and did not receive nelarabine (exclude Low Risk, CNS3, M3 Day 29, and EOC MRD \\>0.1%);","id":"OG001","title":"AALL0434 T-ALL Patients"}],"paramType":"NUMBER","populationDescription":"T-ALL patients on AALL1231 who did not receive CRT or bortezomib: IR (exclude CNS3) and SR T-ALL (exclude those who met AALL0434 \\[NCT00408005\\] Low Risk definition). T-ALL on AALL0434 \\[NCT00408005\\] (who received CRT, no nelarabine) excluding Low Risk, CNS3, M3 Day 29, and EOC MRD \\>0.1%","reportingStatus":"POSTED","timeFrame":"3 years","title":"EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}